Literature DB >> 12297846

Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study.

Pierre Pradat1, Alfredo Alberti, Thierry Poynard, Juan-Ignacio Esteban, Ola Weiland, Patrick Marcellin, Salvatore Badalamenti, Christian Trépo.   

Abstract

The aim of this retrospective study was to determine the predictive value of alanine aminotransferase (ALT) levels for histologic findings in patients with chronic hepatitis C virus (HCV) infection. Data on 864 HCV RNA-positive patients were collected. ALT values were obtained at the time of biopsy (before treatment), and normal ALT values were defined as normal values obtained at serial evaluations during a 6-month period. Histologic results were scored using the METAVIR system. Among all patients, 99% of those with elevated ALT levels had a score of at least F1 (positive predictive value [PPV], 99%) and 88% had a score greater than A1F1. Among patients with persistently normal ALT values, 65% had a score of at least F1 (negative predictive value [NPV], 35%) and 26% had a score greater than A1F1. The receiver operating characteristics analysis indicates that the ALT threshold for the best compromise sensitivity-specificity was about 2.25 times the upper limit of normal (ULN). In conclusion, almost all HCV RNA-positive patients with elevated ALT levels have some degree of fibrosis. However, an important proportion of patients with persistently normal ALT levels also show some histologic signs of fibrosis; the degree of fibrosis is usually mild but is sometimes more marked, and in rare cases cirrhosis may be present. In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297846     DOI: 10.1053/jhep.2002.35530

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C.

Authors:  Shoukat Ali Arain; Qamar Jamal; Amir Omair
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  [Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet)].

Authors:  P Schirmacher; W E Fleig; A Tannapfel; C Langner; V Dries; L Terracciano; H Denk; H P Dienes
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

Review 3.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?

Authors:  Rosilene G Badiani; Vitória Becker; Renata M Perez; Carla A L Matos; Lara B Lemos; Valéria P Lanzoni; Luis Eduardo C Andrade; Alessandra Dellavance; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

5.  Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Saumya Jayakumar; Stephen A Harrison; Rohit Loomba
Journal:  Curr Hepatol Rep       Date:  2016-04-21

6.  Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.

Authors:  Naoki Harada; Naoki Hiramatsu; Tsugiko Oze; Ryoko Yamada; Mika Kurokawa; Masanori Miyazaki; Takayuki Yakushijin; Takuya Miyagi; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Masahide Oshita; Eiji Mita; Hideki Hagiwara; Yoshiaki Inui; Kazuhiro Katayama; Shinji Tamura; Harumasa Yoshihara; Yasuharu Imai; Atsuo Inoue; Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2012-09-14       Impact factor: 7.527

7.  Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Kazuhiko Hayashi; Takashi Honda; Teiji Kuzuya
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

8.  Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Steven F Bronk; Sophie Cazanave; Nathan W Werneburg; Justin L Mott; Patricia C Contreras; Gregory J Gores
Journal:  Hepatol Res       Date:  2009-07-13       Impact factor: 4.288

Review 9.  Controversies in liver biopsy: who, where, when, how, why?

Authors:  Lawrence S Friedman
Journal:  Curr Gastroenterol Rep       Date:  2004-02

10.  Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.

Authors:  Daniele Accapezzato; Vittorio Francavilla; Marino Paroli; Marco Casciaro; Lucia Valeria Chircu; Agostino Cividini; Sergio Abrignani; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.